| Pharmaceutical Information |
| Drug Name |
Daratumumab |
| Drug ID |
BADD_D00582 |
| Description |
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.[A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.[A199002]
Daratumumab was granted FDA approval on 16 November 2015.[L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296] |
| Indications and Usage |
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma.[L13290] It is available as a combination product with [hyaluronidase] for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.[L13296] |
| Marketing Status |
approved |
| ATC Code |
L01FC01 |
| DrugBank ID |
DB09331
|
| KEGG ID |
D10777
|
| MeSH ID |
C556306
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
57894-502; 57894-505; 71124-0007 |
| UNII |
4Z63YK6E0E
|
| Synonyms |
daratumumab | humax-CD38 | humax-CD 38 | Darzalex |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
945721-28-8 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
